Australia, starting July 1, has become the first country to authorize the use of MDMA and psilocybin as treatments for specific mental health conditions, such as post-traumatic stress disorder and treatment-resistant depression. While the decision to allow psychiatrists to prescribe these psychedelic drugs is a bold move, there are concerns among some experts that it may be premature.
“We've got no data on long-term outcomes at all, so that worries me a lot, which is one of the reasons why I'm doing my very large study,” Professor Susan Rossell of Swinburne University explained in an interview. Professor Rossell leads a $5 million-dollar clinical trial testing the potential of psilocybin in the treatment of depression.
It is clear that the scientific community’s perspective on psychedelic drugs is undergoing a significant shift, moving from mere curiosity to a more rigorous exploration of their potential clinical benefits..... more
Comments